Cell Therapy Market Share

North American Market Statistics

Asia Pacific industry is predicted to account for largest revenue share of 59% by 2037. The market growth in the region is also expected on account of growing advancements in medical research. The American healthcare system has made large financial investments in the production of pharmaceuticals and medical research, which is likely to result in continuous advancement in cell therapy technologies in the region.

Also, in 2022, U.S. health spending climbed by over 3% to reach around USD 4 trillion. This may serve as a model for assisting patients with lower incomes to finance additional gene and cell therapies in the region.

Canada has authorized more than 2 cellular therapy products in total for use in patient care as of 2021, which comprise the treatment of adult B-cell lymphoma, Graft V Host disease, and acute lymphoblastic leukemia (ALL) with stem cells.

APAC Market Analysis

The Asia Pacific region will also encounter huge growth for the cell therapy market during the forecast period and will hold the second position as it is the fastest-growing region in the world for gene and cell therapy trials led by the comparatively inexpensive cost of performing clinical trials, which has driven numerous international corporations to profit from the reduced expenses and greater patient volumes.

The region also leads the world in CAR-T trials, with China hosting more than 55% of all CAR-T trials conducted between 2015 and 2022.

Additionally, to obtain a competitive edge and fulfill the growing demand for cell therapies arising from the growing senior population in Japan prominent Japanese firms including Fujifilm, Takeda Pharmaceutical, and Astellas Pharma have entered into deals in the CAR T-Cell therapy field.

In February 2023, more than 12 cell therapies were licensed by the Ministry of Food and Drug Safety (MFDS) of South Korea.